Cutaneous T-Cell Lymphoma (CTCL) is a rare form of cancer affecting immune cells, particularly T-cells, in the skin. It is classified as a Non-Hodgkin lymphoma and is one of the least common types. CTCL preferentially affects men, occurring in men about twice as commonly as women and appearing in mid to late adulthood between the ages of 40 and 70. This infographic was designed to provide basic information about the disease and some of the most common treatment options:
healtheo360 Wellness Blog
Cutaneous T-Cell Lymphoma (CTCL) is a type of lymphoma, or cancer of the immune cells, that arises in T-cells in the skin (primarily). T-cells are an integral part of the immune system, helping to recognize and fight against viruses, bacteria, and even other types of cancers. CTCL is a rare form of non-Hodgkin lymphoma and is most common in the skin, but may affect the blood, lymph nodes, and other internal organs as well. This disease affects men more often than women, and usually occurs between the ages of 40 and 70. There are many forms of treatment that are used to slow the progression of CTCL, but none that serve as curative. Recently, however, there have been a number of emerging biologic and targeted therapies that can have impressive success with treating CTCL. This article will focus on the diagnosis/treatment planning of CTCL as well as describe several widely used treatments for CTCL.
Cutaneous T-Cell Lymphoma (CTCL) is a rare type of cancer that begins in the white blood cells, called T-lymphocytes (T-cells), and attacks the skin. T-cells are important to the immune system and help the body fight infection(s). However, with an abnormal and rapid production of these cells, T-cells can accumulate in the body and cause cancer. CTCL also can involve the blood, the lymph nodes, and other internal organs. Check out this infographic to learn more about CTCL: